Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 9
Submit an article Journal homepage
1,320
Views
10
CrossRef citations to date
0
Altmetric
Research Paper

Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season

Sonja Gandhi-Bangaa Sanofi Pasteur, Toronto, ON, CanadaView further author information
,
Anne-Laure Chabanonb Sanofi Pasteur, Lyon, FranceCorrespondence[email protected]
View further author information
,
Cecile Eyminb Sanofi Pasteur, Lyon, FranceView further author information
,
Timothy Caroec Lighthouse Medical Practice, Eastbourne, East Sussex, UKView further author information
,
Karina Butlerd Our Lady’s Children’s Hospital, Dublin, Crumlin, IrelandView further author information
&
Annick Moureaue Sanofi Pasteur, Marcy l’Etoile, FranceORCID Iconhttps://orcid.org/0000-0002-5306-2833View further author information
ORCID Icon
Pages 2154-2158 | Received 15 Nov 2018, Accepted 05 Feb 2019, Published online: 27 Mar 2019

References

  • World Health Organization. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76.
  • European Medicines Agency. Pharmacovigilance risk assessment committee (PRAC). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London; 2014 April 10 [ accessed 2018 May 28]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf.
  • Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726–30. doi:10.4161/hv.34369.
  • Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294–98.
  • Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, Gasparini R, Durando P, Icardi G. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2015;11(1):91–94. doi:10.4161/hv.34360.
  • Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip(R)): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017;16(6):545–64. doi:10.1080/14760584.2017.1324302.
  • Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther. 2011;11(3):415–27. doi:10.1517/14712598.2011.557658.
  • Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;22:18. doi:10.2807/1560-7917.es.2017.22.18.30527.
  • Chabanon AL, Bricout H, Ballandras C, Souverain A, Caroe TD, Butler KM. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 µg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Hum Vaccin Immunother. 2018;14(2):378–85. doi:10.1080/21645515.2017.1405882.
  • Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I, Samson SI. Quadrivalent inactivated influenza vaccine (VaxigripTetra). Expert Rev Vaccines. 2018;17(1):1–11. doi:10.1080/14760584.2018.1407650.
  • Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K. Adverse events after Fluzone (R) Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011–2013. Vaccine. 2013;31(43):4984–87. doi:10.1016/j.vaccine.2013.08.001.
  • Pasteur S. Intanza 15 μg - SmPC. 2017 Sept 14 [ accessed 2018 July 3]. https://www.medicines.org.uk/emc/product/6550/smpc.
  • Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, Caiazzo AL, Panico MG, Giugliano F, Parlato A, et al. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Adv Ther. 2012;29(4):312–26. doi:10.1007/s12325-012-0012-1.
  • Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum Vaccin Immunother. 2012;8(1):67–75. doi:10.4161/hv.8.1.18419.
  • Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)–United States, 1991–2001. MMWR Surveill Summ. 2003;52:1–24.
  • Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P, Leeb A, Blyth CC, Gold MS, Snelling T, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10):e023263. doi:10.1136/bmjopen-2018-023263.
  • de Lusignan S, Dos Santos G, Byford R, Schuind A, Damaso S, Shende V, McGee C, Yonova I, Ferreira F. Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in english primary care: interim analysis. Adv Ther. 2018. doi:10.1007/s12325-018-0747-4.
  • Clothier HJ, Crawford NW, Russell M, Buttery JP. Adverse events following vaccination of older people may be under-reported. Med J Aust. 2017;207:301–02.
  • Public Health England. Flu plan: winter 2017/18. London; 2017 March [ accessed 2018 May 28]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/600532/annual_flu_plan_2017to2018.pdf.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.